The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era.

Am J Med · 2023 · PMC9993659 · PMID 36898600

Europe PMC DOI

hedged sentence

0.3300

closest p · 6.6× alpha

0.3300

boldest claim

The sentences

did not reach statistical significanceP = .33not close (p > 0.1)

However, NR treatment did not reach statistical significance in the rate of primary composite outcomes among immunocompromised patients (% diff −2.1, [95% CI: −6.0, 1.7], P = .33), but the relative risk reduction of 44% is clinically meaningful.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.